Analysis shows differing outcomes for immune checkpoint inhibition and tyrosine kinase inhibition in metastatic renal cancer, suggesting important prognostic implications.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Isoda et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: